GENEWIZ Launches Novel Antibody Sequencing Methodology, FuzeSeq(TM)
(firmenpresse) - SOUTH PLAINFIELD, NJ -- (Marketwired) -- 03/18/15 -- Leading global genomics company, , today announced the launch of , a proprietary methodology that optimizes next generation sequencing of in vitro antibody selection libraries.
GENEWIZ developed FuzeSeq™ Antibody to address the existing limitations of conventional Sanger sequencing and next generation sequencing of in vitro antibody selection libraries. FuzeSeq™ Antibody re-engineers the in vitro selection vector by fusing the antibody VH and VL regions together for next generation sequencing. The resulting data provides million-fold coverage compared to Sanger sequencing, while simultaneously circumventing the limitations of pairing full length variable regions encountered with traditional next generation sequencing approaches.
"When designing the FuzeSeq™ methodology, our focus was to not only produce enhanced data quality and quantity for the next generation sequencing of in vitro selection libraries, but also offer a streamlined solution to increase the efficiency of researchers' antibody discovery workflows," stated Dr. Ginger Zhou, Head of . "FuzeSeq™ achieves these goals by sequencing the full length of the fused VH-VL pairs, which provides a comprehensive overview of the diversity in the naïve or enriched antibody pools."
Zhou continued, "The reliability of FuzeSeq™ Antibody data ensures the precise and reproducible identification of the full antibody diversity. An early adopter of FuzeSeq™ Antibody reported that the depth of sequencing allowed for the identification of less frequent antibody sequences that was not feasible with Sanger sequencing, and in a cost-efficient manner. In addition to screening multiple rounds of panning against different antigen targets, they were able to analyze the diversity of the naïve library prior to selection within one sequencing run."
GENEWIZ is a global contract research organization (CRO) specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, genomic, bioinformatics, and GLP regulatory-compliant services. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions.
Headquartered in South Plainfield, NJ, GENEWIZ is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; Langen, Germany; and Tokyo, Japan.
GENEWIZ
Global Headquarters
115 Corporate Boulevard
South Plainfield, NJ 07080
+1-908-222-0711
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.03.2015 - 10:00 Uhr
Sprache: Deutsch
News-ID 379299
Anzahl Zeichen: 0
contact information:
Town:
SOUTH PLAINFIELD, NJ
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 310 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"GENEWIZ Launches Novel Antibody Sequencing Methodology, FuzeSeq(TM)"
steht unter der journalistisch-redaktionellen Verantwortung von
GENEWIZ (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
